MedPath

Comparison of the effects of Pramipexole and Gabapentin on the treatment of restless leg syndrome in patients undergoing hemodialysis

Phase 3
Conditions
Restless legs syndrome.
Restless legs syndrome
G25.81
Registration Number
IRCT20191106045350N1
Lead Sponsor
Qazvin University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Patients with end-stage chronic renal failure (at least 6 months) under permanent hemodialysis
Having restless legs syndrome (RLS) based on International RLS Study Group (IRSLSS) diagnostic criteria
Moderate to severe RLS based on IRSLSS diagnostic criteria

Exclusion Criteria

Pregnancy
Iron deficiency anemia
Concomitant neurodegenerative diseases such as cerebrovascular accident (CVA) and Parkinson's disease
Lyme disease
Complications such as nausea, vomiting, and abdominal pain due to medication use

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Disease severity. Timepoint: Before the study and after 4 weeks of treatment. Method of measurement: Severity scale based on International Restless Legs Syndrome Study Group (IRSLSS) diagnostic criteria.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath